A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs ATB 200 (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Acronyms STRIDE
- Sponsors Amicus Therapeutics
- 06 Oct 2018 This trial has been completed in Belgium.
- 03 Oct 2018 Status has been changed to discontinued.
- 03 Jul 2018 New trial record